Tilray Medical announced an expansion of its Australian medical cannabis portfolio, adding new products under the Redecan and Good Supply brands. The new lines include flower, extracts, vapes and pastilles, broadening patient access to high‑potency, clinically supported solutions.
The move builds on Tilray’s long‑standing presence in Australia, where it supplies EU‑GMP certified medical cannabis through prescriber, pharmacy and clinical distribution channels. The expanded product mix is designed to meet diverse patient needs and preferences in the regulated market.
The expansion aligns with Tilray’s broader international growth strategy. In Q1 FY2026 the company reported a 10% year‑over‑year increase in international cannabis revenue, driven by strong demand in core markets and offsetting headwinds in legacy segments. Net revenue for the quarter reached $210 million, with a net income of $1.5 million, marking a turnaround from a loss in the prior year.
Rajnish Ohri, President of International, said Australia represents an important strategic market and that the launch reflects Tilray’s long‑term commitment to delivering quality, differentiated cannabis products. He added that the company will leverage proven genetics, rigorous quality standards and local market expertise to support the evolving needs of the Australian community.
While the Australian medical cannabis market is growing, analysts note a challenging environment with market weakness. Tilray’s expansion seeks to capture a larger share of the market, but the company must navigate regulatory and competitive headwinds. The new product portfolio is expected to strengthen Tilray’s position as a global provider of pharmaceutical‑grade products.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.